Search for a trial

A PHASE III MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB COMPARED WITH TERIFLUNOMIDE IN ADULT PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS

The goal of the fenebrutinib development program in MS is to evaluate the benefits and risks of fenebrutinib treatment across the spectrum of patients with MS. Based on the existing toxicology, pharmacology, and clinical experience with fenebrutinib…

Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients with Progressive Multiple Sclerosis

This study has been transitioned to CTIS with ID 2024-514617-35-00 check the CTIS register for the current data. Primary Objective1. To evaluate the efficacy of IMU-838 versus placebo as measured by quantitative magnetic resonance imaging (MRI)…

A Phase 2, multicenter, open-label, non-randomized, proof-of-concept study evaluating the efficacy, safety, and tolerability of SAR445088 (previously BIVV020) in adults with chronic inflammatory demyelinating polyneuropathy (CIDP)

This study has been transitioned to CTIS with ID 2024-512345-16-00 check the CTIS register for the current data. The purpose of this BIVV020 Phase 2 study is to determine the preliminary efficacy, safety, and tolerability of BIVV020 in three CIDP…

DE-escalating ocRelizumAb In cLinical and radiological stable MS

To describe the efficacy and safety of a maintenance versus induction anti-CD20 treatment strategy in pwMS.

STOPPING OF DISEASE MODIFYING TREATMENTS AND OLIGOCLONAL BANDS IN PEOPLE WITH MULTIPLE SCLEROSIS

Primary Objective: • To compare the proportion of MS patients with OCBs between patients with and patients without recurrent disease 12 months after cessation of DMTs. Secondary Objectives: • To explore differences in CSF/ blood IgG indices between…

A Phase III, multicenter, randomized, parallel-group, double blinded, placebo controlled study to evaluate the efficacy and safety of ocrelizumab in adults with Primary Progressive Multiple Sclerosis

Primary:To investigate the efficacy of ocrelizumab compared with placebo in patients with primary progressive multiple sclerosis, as measured by thetime to onset of confirmed disability progression over the treatment period, defined as an increase…

An Open-Label, single-arm study to evaluate the effectiveness and safety of Ocrelizumab in patients with early stage relapsing remitting multiple sclerosis

This study will evaluate the efficacy and safety of ocrelizumab in patients with early stage relapsing remitting multiple sclerosis (RRMS).The objective of the Immune Substudy is to explore immunological changes associated with ocrelizumab treatment…

An Open-Label Extension Study to Investigate the Long-Term Safety, Tolerability, and Efficacy of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

CIDP04 is a Phase 2A, multicenter, single-arm, open-label study with the primary objective of evaluating the long-term safety and tolerability of rozanolixizumab when administered as weekly subcutaneous (sc) infusion in subjects with CIDP. The…

Efficacy of add-on high-dose simvastatin on markers for disease progression in MS patients treated with ocrelizumab and natalizumab (SIMSON), a phase II clinical trial.

To assess the efficacy of add-on high-dose simvastatin on markers for disease progression in MS patients treated with natalizumab or ocrelizumab for at least six months.

Optimal neurophysiological parameters in neuromuscular electrical stimulation in the treatment of dysphagia in multiple sclerosis - a pilot study

Primary Objective: To develop a protocol for NMES for dysphagia to determine optimal electrode placement and stimulation parameters in MS patients.Secondary Objective: To determine variability in location, morphology, and type of motor dysfunctions…

A Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Single and Multiple Doses of AL002 in Healthy Participants and in Participants with Mild to Moderate Alzheimer*s Disease.

The primary objective of the study is to evaluate the safety, tolerability, PK, and PD of AL002 administered in single ascending doses in healthy participants and multiple doses in participants with mild to moderate AD.

Phase I, Single-Center, Randomized, Placebo-Controlled, Double-Blinded Study with Single Ascending Doses, Evaluating the Safety and Tolerability of T20K, Administered by a 1-hr IV Infusion in Healthy Male Volunteers

Primary objective: To determine the safety and tolerability of single ascending i.v. doses of T20K administered to healthy male subjects up to detectable levels of T20K within the defined dose rangeSecondary objective: To explore the plasma profile…

A PHASE IIIB MULTICENTER, RANDOMIZED, DOUBLE-BLIND, CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY AND PHARMACOKINETICS OF A HIGHER DOSE OF OCRELIZUMAB IN ADULTS WITH RELAPSING MULTIPLE SCLEROSIS

This study will evaluate the efficacy, safety, and pharmacokinetics of a higher dose of ocrelizumab compared with the approved dose of ocrelizumab in patients with relapsing forms of multiple sclerosis.

Neuroprotective Effects of Exercise in People with Progressive Multiple Sclerosis: a phase II trial

The primary aim of this phase II trial is to assess whether a progressive resistance training program can slow down neurodegeneration in people with PMS. Additional objectives of this study are: 1. To determine the effect of exercise on disability.…

AN OPEN-LABEL, SINGLE-ARM 4-YEAR STUDY TO EVALUATE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB TREATMENT IN PATIENTS WITH PROGRESSIVE MULTIPLE SCLEROSIS

This study has been transitioned to CTIS with ID 2023-506429-13-00 check the CTIS register for the current data. This study will evaluate the effectiveness and safety of ocrelizumab in PMS patients.

A Phase 2 Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of AL002 in Participants with Early Alzheimer*s Disease

To evaluate the efficacy of AL002 in participants with Early AD in delaying disease progression compared to standard of care

Neurophysiological effects of transcutaneous electrical nerve stimulation in persons with MS - a pilot study

The primary objective of this pilot study is therefore to investigate the effects of TENS on brain activity in pwMS measured with fMRI.

Innovative training method in patients with Multiple Sclerosis and Spinal Cord Injury, a pilot study.

The main objective of this pilot study is to explore the changes in physical fitness in patients with MS or SCI who participate in this training program. Secondary, we will explore the changes in walking efficiency, fatigue, quality of life, and the…

Assessing fatigue, disease activity and progression through smartphone surveillance in multiple sclerosis

to develop and explore measuring methods using conventional smartphones to quantify fatigue, disease activity, and short term and long progression in a day-to-day setting in patients with MS. Key research questions: - Are the NeuroKeys and MS Sherpa…

A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects with Relapsing-Remitting Multiple Sclerosis

Primary: To evaluate the long-term safety profile of BG00012.Additional: To evaluate the long-term efficacy of BG00012 using clinical endpoints (including relapse and annualized relapse rate [ARR]) and disability progression (Expanded Disability…